Cloud Pharmaceuticals announced Monday the expansion of its drug design and development program, and that the company has been granted supercomputing time at Argonne National Laboratory to design inhibitors of multiple parasitic targets.

Through a discretionary allocation of 1 million core-hours at the Argonne Leadership Computing Facility (ALCF), researchers at Cloud Pharmaceuticals will use Mira, a 10-petaflops IBM Blue Gene/Q supercomputer to investigate inhibitors of the dihydrofolate reductase enzyme, or DHFR, from multiple sources.